tetano
Editor, Senior Moderator
J Am Heart Assoc. 2020 Apr 29:e017013. doi: 10.1161/JAHA.120.017013. [Epub ahead of print]
Current perspectives on Coronavirus 2019 (COVID-19) and cardiovascular disease: A white paper by the JAHA editors.
Gupta AK[SUP]1,[/SUP][SUP]2,[/SUP][SUP]3[/SUP], Jneid H[SUP]4[/SUP], Addison D[SUP]5[/SUP], Ardehali H[SUP]6[/SUP], Boehme AK[SUP]7,[/SUP][SUP]8[/SUP], Borgaonkar S[SUP]4[/SUP], Boulestreau R[SUP]9[/SUP], Clerkin K[SUP]10[/SUP], Delarche N[SUP]9[/SUP], DeVon HA[SUP]11[/SUP], Grumbach IM[SUP]12[/SUP], Gutierrez J[SUP]7[/SUP], Jones DA[SUP]1,[/SUP][SUP]3[/SUP], Kapil V[SUP]1,[/SUP][SUP]2[/SUP], Maniero C[SUP]1,[/SUP][SUP]2[/SUP], Mentias A[SUP]13[/SUP], Miller PS[SUP]14[/SUP], May Ng S[SUP]3[/SUP], Parekh JD[SUP]12[/SUP], Sanchez RH[SUP]5[/SUP], Teodor Sawicki K[SUP]6[/SUP], S J M Te Riele A[SUP]15[/SUP], Ann Remme C[SUP]16[/SUP], London B[SUP]12[/SUP].
Author information
Abstract
Coronavirus Disease 2019 (COVID-19), caused by the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), has infected more than 3.0 million people worldwide and killed more than 200,000 as of April 27, 2020, making it the most lethal pandemic since the Spanish flu of 1918.[SUP]1, 2[/SUP] COVID-19 may preferentially infect individuals with cardiovascular conditions, is more severe in subjects with cardiovascular comorbidities, may directly or indirectly affect the heart and may interact with cardiovascular medications.[SUP]3[/SUP] In addition, the widespread effects of the pandemic on the global healthcare system affects the routine and emergency cardiac care for patients who are, may be, or are not infected with COVID-19.
KEYWORDS:
COVID‐19; Cardiovascular disease; Coronavirus disease 2019; SARS‐CoV‐2; cardiovascular risk factors; management; treatment
PMID:32347144DOI:10.1161/JAHA.120.017013
Free full text
Current perspectives on Coronavirus 2019 (COVID-19) and cardiovascular disease: A white paper by the JAHA editors.
Gupta AK[SUP]1,[/SUP][SUP]2,[/SUP][SUP]3[/SUP], Jneid H[SUP]4[/SUP], Addison D[SUP]5[/SUP], Ardehali H[SUP]6[/SUP], Boehme AK[SUP]7,[/SUP][SUP]8[/SUP], Borgaonkar S[SUP]4[/SUP], Boulestreau R[SUP]9[/SUP], Clerkin K[SUP]10[/SUP], Delarche N[SUP]9[/SUP], DeVon HA[SUP]11[/SUP], Grumbach IM[SUP]12[/SUP], Gutierrez J[SUP]7[/SUP], Jones DA[SUP]1,[/SUP][SUP]3[/SUP], Kapil V[SUP]1,[/SUP][SUP]2[/SUP], Maniero C[SUP]1,[/SUP][SUP]2[/SUP], Mentias A[SUP]13[/SUP], Miller PS[SUP]14[/SUP], May Ng S[SUP]3[/SUP], Parekh JD[SUP]12[/SUP], Sanchez RH[SUP]5[/SUP], Teodor Sawicki K[SUP]6[/SUP], S J M Te Riele A[SUP]15[/SUP], Ann Remme C[SUP]16[/SUP], London B[SUP]12[/SUP].
Author information
Abstract
Coronavirus Disease 2019 (COVID-19), caused by the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), has infected more than 3.0 million people worldwide and killed more than 200,000 as of April 27, 2020, making it the most lethal pandemic since the Spanish flu of 1918.[SUP]1, 2[/SUP] COVID-19 may preferentially infect individuals with cardiovascular conditions, is more severe in subjects with cardiovascular comorbidities, may directly or indirectly affect the heart and may interact with cardiovascular medications.[SUP]3[/SUP] In addition, the widespread effects of the pandemic on the global healthcare system affects the routine and emergency cardiac care for patients who are, may be, or are not infected with COVID-19.
KEYWORDS:
COVID‐19; Cardiovascular disease; Coronavirus disease 2019; SARS‐CoV‐2; cardiovascular risk factors; management; treatment
PMID:32347144DOI:10.1161/JAHA.120.017013
Free full text